Archive for November 2010
28 November 2010
The fair culminated at Shakuntalam Theatre where participants were awarded for putting up a good show. There were seven awards on offer, including the Chairman’s Certificate for Excellence in Display which has been introduced this year. The pavilions were judged based on their display and design in keeping with this year’s theme `Energytech and Envirotech’.
Giving away the awards, chief minister Sheila Dikshit said, “These awards reflect the condition of the states and the efforts they have put in towards development.”
While Gujarat won the gold in the states/union territories category, Meghalaya bagged the first position in the northeastern states category. Afghanistan won the gold medal in foreign category and the ministry of health and family welfare was adjudged the best in the category of ministries and departments.
Among PSUs, commodity boards and banks, the Council of Scientific and Industrial Research won the gold followed by National Mission on Bamboo Application which got the silver medal. The Coir Board received a special commendation…….
27 November 2010
Chandigarh-based Institute of Microbial Technology (Imtech) has made it possible to cost-cut expenditures and already filed two patents.
“This third generation drug is clot-specific…. prevents bleeding and targets only the affected area,” said Dr Girish Sahni, Imtech director and leader of the team which developed the drug.
The institute has inked an Rs 750-crore deal with New Jersey-based company for preclinical trials. “We have licensed this product to Nostrum, which will conduct trials and market it. We will get a royalty of 2.5% of the product cost,” said Girish.
Imtech had developed streptokinase (clot dissolver) in India in 2002. It was subsequently developed as first and second generation drug by 2009. The fourth generation drug will prevent re-occurrence of clot. “What it implies is that the drug can stay for some more time than the present 15-20 minute span and effectively work at the clot site without causing much toxicity,” he revealed.
27 November 2010
CHANDIGARH: Nostrum Pharmaceuticals, the US, has obtained the worldwide licence to develop and commercialise the third and fourth generation thrombolytic molecules developed by city-based Institute of Microbial Technology (IMTECH).
The technology has been transferred by IMTECH as part of a 150-million US dollars deal in milestone payments and royalties.
The agreement was signed in New Delhi in the presence of Union Minister of Science and Technology Kapil Sibal and Prof Samir K Brahmachari, Director General, Council for Scientific and Industrial Research.
In the recent past, IMTECH has developed safe, low-cost clot busters that have received a good response from the medical fraternity. These were developed after a long research by IMTECH director Dr Girish Sahni and his team. Dr Sahni said the fourth generation clot-busters also prevent re-occlusion.
27 November 2010
He obtained his MSc (1977) degree from Lucknow University (LU) and PhD Degree from University of Baroda in 1982. After spending about 10 years in Canada and USA working on various positions like post doctoral fellow to production manager in a biotechnology company in USA, he moved to NBRI in February 1994 as scientist in the plant microbiology division and became Scientist-G in February 2009.
His research interests include area of fundamental and applied aspects of plant-microbe interactions and relate to elucidation of relationships between microbial populations and environmental stresses. He has also been bestowed with five national awards.
Nostrum Pharmaceuticals, LLC Licenses Clinical Development and Worldwide Commercialization Rights From IMTECH, India, for Novel, Next-Generation Thrombolytics With Clot Specific Activation and Re-occlusion Prevention Properties
24 November 2010
NEW BRUNSWICK, N.J: Nostrum Pharmaceuticals, LLC (“Nostrum”), a privately held pharmaceuticals company based in New Brunswick, New Jersey, announced today its licensing agreement with Institute of Microbial Technology (“IMTECH”), Chandigarh, India, a research institute under Council of Scientific and Industrial Research (“CSIR”), a Government of India organization. Pursuant to such agreement, Nostrum will in-license next generation thrombolytics from IMTECH for clinical development and worldwide commercialization.
Nirmal Mulye, Ph.D., President of Nostrum, said, “These novel, next generation thrombolytics are clot specific plasminogen activator proteins, and each one of these molecules has a uniquely different value-added properties such as longer half-life in blood circulation and re-occlusion prevention during heart attack. Moreover, these unique properties of the molecules will help to effectively mitigate a number of systemic side effects, such as bleeding, usually associated with the prevalent thrombolytic protein molecules in the market today.” Dr. Mulye further said, “Our collaboration with CSIR is an example of successful public-private partnership. This is our third collaboration with IMTECH/ CSIR. Clearly they have been developing world-class technologies and setting an example of pursuing commercially viable innovations.”
These new molecules were invented at IMTECH in the laboratory headed by Girish Sahni, Ph.D., who is also the director of IMTECH. Dr. Sahni said, “Re-occlusion of the blood vessel after thrombolytics treatment remains one of the main cause for patient death after the heart attack and continues to be both a practical and scientific challenge to reckon with.” Dr. Sahni added, “My group at IMTECH had been working for a very long time to come up with an approach that will resolve the issue of blood vessel re-occlusion after thrombolytics treatment. I am glad that one of our new thrombolytic molecules has shown that promise in the laboratory experiments. Based on these results we are confident that it will develop into a world class drug with a most sought after property of not only clot specificity of activation but also re-occlusion prevention.” Dr. Sahni further added, “Collaborating with Nostrum over the years has been a very fulfilling experience. They have demonstrated a true commitment to take forward our collaborations as seen by the remarkable pace at which they have taken forward the development of our first thrombolytic Clot Specific Streptokinase (CSSK).”…..
25 November 2010
According to Master Plan-2021, the ceiling on vertical growth in most parts of the city is 15 meters and buildings which have been constructed violating this norm may face action. MCD standing committee chairman Yogender Chandolia said illegal floors in such buildings “may be demolished”.
Though the MCD survey is currently concentrating on buildings around the Yamuna riverbed, the agency plans to extend it to other parts of the city. “A survey to identify dangerous buildings will be carried out across the city in a phased manner and action will be taken to ensure structural stability. The Central Building Research Institute (CBRI) will help us with the survey.” Mehra said CBRI experts will be back in Delhi on Wednesday.
“The CBRI experts have collected samples from the building that collapsed at Lalita Park in Laxmi Nagar and inspected other constructions in the area. They will tell us whether the buildings can be repaired through retrofitting. The cost will, most probably, be borne by the owner of the buildings as they are all privately owned,” Mehra said. Chandolia, however, said the civic agency may bear the cost of repairing the buildings……….
24 November 2010
SHIMLA: For the 78,000-odd residents of pictureque Rekong Peo, about 250km from Shimla, the winter has come with a sinking feeling: scores of houses and government offices have developed cracks, which are widening by the day triggering panic in the town. Rekong Peo is the headquarters of the tribal Kinnaur district.